Prothena doses first patient in Phase I study of NEOD001

Clinical stage biotechnology company Prothena has dosed the first AL amyloidosis patient in its Phase I study of NEOD001, an antibody therapeutic candidate.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news